What Patient Registries Do & Why They Matter
A patient registry organizes consented, de-identified data from many people over time so researchers can learn from patterns no single clinic could see alone. The PROMPT registry — built across academic centers including Memorial Sloan Kettering and Penn Medicine — is a working example of how this strengthens the interpretation of genetic test results.
Patient Registries
A multi-institutional registry, explained
A patient registry is a structured, ongoing collection of health information from people who share a condition, exposure, or experience — here, undergoing multi-gene panel testing for hereditary cancer risk. A multi-institutional registry pools that information across more than one center, so the combined dataset reflects a far larger and more diverse group of patients than any one hospital could enroll on its own.
The PROMPT Study — Prospective Registry Of MultiPlex Testing — was organized as exactly this kind of collaboration. It was established through participating institutions that included Memorial Sloan Kettering Cancer Center and Penn Medicine, with laboratory involvement from Pathway Genomics, to follow patients who had received results from multi-gene panels. By aggregating these experiences, a registry turns scattered individual results into a research resource that can be studied as a whole.
From consent to aggregated data
Registries follow a deliberate sequence designed to protect the individual while making the collective data useful for research.
Informed consent
Participation is voluntary. A patient chooses to enroll and consents to having their genetic test results and relevant health history contributed to the registry for research. Consent defines what may be collected and how it may be used.
Data collection
The registry gathers the panel test result — which genes were tested and what variants were found — along with documented clinical information such as personal and family cancer history. This is the longitudinal record that accrues over time.
De-identification
Before data is aggregated for research, direct identifiers are removed or coded so individual records cannot be readily traced back to a named person. This safeguard lets researchers study patterns without exposing identities.
Aggregation and analysis
De-identified records from every participating center are combined into one dataset. With many patients pooled together, researchers can examine how often specific variants occur and how they associate with cancer outcomes.
A registry observes; a trial intervenes
Registries and clinical trials are often confused, but they answer different questions. A clinical trial is an experiment: participants are assigned to an intervention — a drug, procedure, or screening strategy — and researchers measure its effect, frequently against a comparison group. Trials are designed to test whether something works.
A registry is observational. No treatment is assigned by the researchers. Instead, the registry records what happens to patients in the course of their real care — in PROMPT's case, people who already underwent panel testing — and studies the resulting data over time. This makes registries well suited to questions of natural history, frequency, and long-term outcomes across large, real-world populations, rather than to proving cause and effect for a specific intervention.
Longitudinal data sharpens variant interpretation
When a panel test reports a gene variant, the central question is what that variant means for cancer risk. Many variants — particularly those classified as variants of uncertain significance — are difficult to interpret precisely because they are individually rare. A single clinic may see a given variant only once.
A registry addresses this by accumulating observations of the same variants across many patients and many centers. As more longitudinal data is gathered, researchers can better estimate how frequently a variant appears and how it tracks with cancer in real populations. Over time, this collective evidence can help refine risk estimates and reclassify uncertain findings as more clearly benign or pathogenic — improving the accuracy of the information patients and clinicians rely on to make decisions.
Frequently asked questions
Is my genetic information kept private in a registry?
Registries are built around privacy safeguards. Participation requires informed consent, and before records are aggregated for research, direct identifiers are removed or coded through de-identification so the data cannot be readily linked back to a named individual. The intent is to enable research on patterns while protecting the people who contributed.
How is a registry different from a clinical trial?
A clinical trial assigns participants to an intervention and tests its effect. A registry is observational — it records and studies what happens to patients in their ordinary care without assigning a treatment. PROMPT followed patients who had already undergone multi-gene panel testing, making it a registry rather than a trial.
What was the PROMPT Study?
PROMPT — the Prospective Registry Of MultiPlex Testing — was a multi-institutional registry that tracked patients who underwent multi-gene panel testing for hereditary cancer risk. It was organized through participating institutions including Memorial Sloan Kettering Cancer Center and Penn Medicine, with laboratory involvement from Pathway Genomics.
How does pooling data improve risk estimates?
Individual variants are often rare, so any one clinic sees too few cases to draw firm conclusions. By combining de-identified records from many patients across institutions, a registry assembles enough observations to study how often a variant occurs and how it associates with cancer — information that can refine risk estimates and help reclassify variants of uncertain significance.
Why is this considered a public good?
Findings from a registry are research-oriented rather than commercial. Improved variant interpretation and risk estimates benefit the broader genetics and oncology community — informing how future patients' results are understood — rather than serving a single product or sale.
Keep building your understanding
Registries are one part of how hereditary-cancer genetics moves from a single sample to a confident interpretation. Explore how panel testing works and how variants are classified — or reach out with a question.